Author/Authors :
Pourmoghaddas، Masoud نويسنده MD, Professor of Interventional Cardiology, Chamran Heart Hospital, Isfahan University of Medical Sciences, Isfahan , , Rabbani، Majid نويسنده Resident, Hypertension Research Center, Isfahan Cardiovascular Research Institute , Isfahan University of Medical Sciences, Isfahan, Iran , , SHAHABI، Javad نويسنده Resident of Cardiology , , Garakyaraghi، Mohammad نويسنده Assistant Professor, Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, , Isfahan University of Medical Sciences, Isfahan, Iran , , Khanjani، Reza نويسنده Resident, Hypertension Research Center, Isfahan Cardiovascular Research Institute , Isfahan University of Medical Sciences, Isfahan, Iran , , Hedayat، Pegah نويسنده Resident, Department of Pathology, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran ,
Abstract :
BACKGROUND: Heart failure is one of the leading causes of mortality, is a final common
pathway of several cardiovascular diseases, and its treatment is a major concern in the science of
cardiology. The aim of the present study was to compare the effect of addition of the coenzyme
Q10 (CoQ10)/atorvastatin combination to standard congestive heart failure (CHF) treatment
versus addition of atorvastatin alone on CHF outcomes.
METHODS: This study was a double-blind, randomized placebo-controlled trial. In the present
study, 62 eligible patients were enrolled and randomized into 2 groups. In the intervention
group patients received 10 mg atorvastatin daily plus 100 mg CoQ10 pearl supplement twice
daily, and in the placebo group patients received 10 mg atorvastatin daily and the placebo of
CoQ10 pearl for 4 months. For all patients echocardiography was performed and blood sample
was obtained for determination of N-terminal B-type natriuretic peptide, total cholesterol, low
density lipoprotein, erythrocyte sedimentation rate, and C-reactive protein levels.
Echocardiography and laboratory test were repeated after 4 months. The New York Heart
Association Function Class (NYHA FC) was also determined for each patient before and after
the study period.
RESULTS: Data analyses showed that ejection fraction (EF) and NYHA FC changes differ
significantly between intervention and placebo group (P = 0.006 and P = 0.002, respectively).
Changes in other parameters did not differ significantly between study groups.
CONCLUSION: We deduce that combination of atorvastatin and CoQ10, as an adjunctive treatment
of CHF, increase EF and improve NYHA FC in comparison with use of atorvastatin alone.
